These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 37634656)
1. A review of polypills for the prevention of atherosclerotic cardiovascular disease. Agnello F; Finocchiaro S; Laudani C; Legnazzi M; Mauro MS; Rochira C; Scalia L; Capodanno D Am Heart J; 2023 Dec; 266():74-85. PubMed ID: 37634656 [TBL] [Abstract][Full Text] [Related]
2. Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk. Lafeber M; Spiering W; Visseren FL; Grobbee DE; Bots ML; Stanton A; Patel A; Prabhakaran D; Webster R; Thom S; Rodgers A; Eur J Prev Cardiol; 2017 Jun; 24(9):951-961. PubMed ID: 28436727 [TBL] [Abstract][Full Text] [Related]
3. The Effect of a Cardiovascular Polypill Strategy on Pill Burden. Truelove M; Patel A; Bompoint S; Brown A; Cass A; Hillis GS; Peiris D; Rafter N; Reid CM; Rodgers A; Tonkin A; Usherwood T; Webster R; Cardiovasc Ther; 2015 Dec; 33(6):347-52. PubMed ID: 26280247 [TBL] [Abstract][Full Text] [Related]
4. Polypill: Progress and Challenges to Global Use--Update on the Trials and Policy Implementation. Webster R; Rodgers A Curr Cardiol Rep; 2015 Dec; 17(12):121. PubMed ID: 26497041 [TBL] [Abstract][Full Text] [Related]
5. Polypill Programs to Prevent Stroke and Cut Costs in Low Income Countries: Moving From Clinical Efficacy to Pragmatic Implementation. Sarfo FS; Nichols M; Opare-Addo PA; Ovbiagele B Stroke; 2023 Feb; 54(2):407-414. PubMed ID: 36689592 [TBL] [Abstract][Full Text] [Related]
8. Strengths and Limitations of Using the Polypill in Cardiovascular Prevention. Roy A; Naik N; Srinath Reddy K Curr Cardiol Rep; 2017 May; 19(5):45. PubMed ID: 28425033 [TBL] [Abstract][Full Text] [Related]
9. Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe. Thom S; Field J; Poulter N; Patel A; Prabhakaran D; Stanton A; Grobbee DE; Bots ML; Reddy KS; Cidambi R; Rodgers A Eur J Prev Cardiol; 2014 Feb; 21(2):252-61. PubMed ID: 23038750 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of a Polypill to Reduce Cardiovascular Events: A Review of Clinical Trials. Kelly MS; Dacey A; Siana A; Ojeda J J Cardiovasc Pharmacol; 2024 Jan; 83(1):8-15. PubMed ID: 37924288 [TBL] [Abstract][Full Text] [Related]
11. Barriers and Facilitators to the Use of Cardiovascular Fixed-Dose Combination Medication (Polypills) in Andhra Pradesh, India: A Mixed-Methods Study. Salam A; Praveen D; Patel A; Tewari A; Webster R Glob Heart; 2019 Sep; 14(3):303-310. PubMed ID: 31451238 [TBL] [Abstract][Full Text] [Related]
12. Embracing the polypill as a cardiovascular therapeutic: is this the best strategy? Franczyk B; Gluba-Brzózka A; Jurkiewicz Ł; Penson P; Banach M; Rysz J Expert Opin Pharmacother; 2018 Dec; 19(17):1857-1865. PubMed ID: 30295098 [TBL] [Abstract][Full Text] [Related]
13. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. Patel A; Cass A; Peiris D; Usherwood T; Brown A; Jan S; Neal B; Hillis GS; Rafter N; Tonkin A; Webster R; Billot L; Bompoint S; Burch C; Burke H; Hayman N; Molanus B; Reid CM; Shiel L; Togni S; Rodgers A; Eur J Prev Cardiol; 2015 Jul; 22(7):920-30. PubMed ID: 24676715 [TBL] [Abstract][Full Text] [Related]
14. A Survey of Availability and Affordability of Polypills for Cardiovascular Disease in Selected Countries. Satheesh G; Gyawali B; Sun MFC; Huffman MD; Banerjee A; Perel P; Murphy A Glob Heart; 2024; 19(1):56. PubMed ID: 38973984 [TBL] [Abstract][Full Text] [Related]
15. Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular disease. Agarwal A; Mehta PM; Jacobson T; Shah NS; Ye J; Zhu J; Wafford QE; Bahiru E; de Cates AN; Ebrahim S; Prabhakaran D; Rodgers A; Huffman MD Nat Med; 2024 Apr; 30(4):1199-1209. PubMed ID: 38532223 [TBL] [Abstract][Full Text] [Related]
16. [Role of polypills in cardiovascular risk reduction in primary prevention]. Botto F; Tajer C; Díaz R; Piñeiro D; Sosa Liprandi Á Medicina (B Aires); 2022; 82(6):904-913. PubMed ID: 36571530 [TBL] [Abstract][Full Text] [Related]
17. The concept of the polypill in the prevention of cardiovascular disease. Wiley B; Fuster V Ann Glob Health; 2014; 80(1):24-34. PubMed ID: 24751562 [TBL] [Abstract][Full Text] [Related]
18. Polypills for the prevention of Cardiovascular diseases. Kolte D; Aronow WS; Banach M Expert Opin Investig Drugs; 2016 Nov; 25(11):1255-1264. PubMed ID: 27645895 [TBL] [Abstract][Full Text] [Related]
19. The Impact of Polypill on Adherence and Cardiovascular Outcomes: A Comprehensive Systematic Review with Meta-Analysis. Salim H; Musmar B; Saifi M; Ayyad M; Ruzieh M; Azar J; Nazzal Z Curr Cardiol Rev; 2024; 20(2):61-71. PubMed ID: 38265377 [TBL] [Abstract][Full Text] [Related]
20. [The Polypill - A Practicable Approach?]. Thürmann PA; Kleinerüschkamp AG; Boehme P Dtsch Med Wochenschr; 2019 Jun; 144(11):715-718. PubMed ID: 31163467 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]